Deerfield Beach, FL -- (SBWIRE) -- 01/31/2017 -- This report provides detailed analysis of worldwide markets for Fondaparinux from 2011-2016, and provides extensive market forecasts (2016-2021) by region/country and subsectors. It covers the key technological and market trends in the Fondaparinux market and further lays out an analysis of the factors influencing the supply/demand for Fondaparinux, and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.

For sample request click on http://www.marketresearchstore.com/report/global-fondaparinux-market-outlook-2016-2021-69453#RequestSample

Fondaparinux, an injectable blood thinner that fights clots in the legs (deep vein thrombosis) and lungs (pulmonary embolism), is a synthetic pentasaccharide, which is difficult to manufacture on a commercial scale. Although it is a better and safer alternative to pharmaceutical heparins in many cases, its high cost, which results from the difficult and tedious synthesis, is a deterrent for its widespread use.

Fondaparinux injection is used to prevent deep vein thrombosis (DVT; a blood clot, usually in the leg), which can lead to pulmonary embolism (PE; a blood clot in the lung), in people who are having hip surgery, hip or knee replacement, or abdominal surgery. It is also used in along with warfarin (Coumadin, Jantoven) to treat DVT or PE. Fondaparinux injection is in a class of medications called factor Xa inhibitors. It works by decreasing the clotting ability of the blood.

Global Fondaparinux Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Fondaparinux market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies.

Major Companies covered in this Research Report are,

Reliable Biopharmaceutical (USA)
Aspen (France)
Apotex (Canada)
GSK (UK)
Alchemia (Australia)
Dr. Reddy's Laboratories (India)
Aurobindo Pharma (India)
ScinoPharm Taiwan (Taiwan)
Formosa Laboratories (Taiwan)
Chase Sun (China)
Wuhan Sunrise (China)
Qinghai Lake Pharmaceutical (China)
Shanghai Acana Pharmtech (China)
Jiangsu Hengrui Medicine (China)
Huadong Pharmaceutical (China)
Brightgene Biomedical (China)

Have Any Query? Ask Our Expert @ http://www.marketresearchstore.com/report/global-fondaparinux-market-outlook-2016-2021-69453#InquiryForBuying

The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Fondaparinux industry has been provided.